AR078304A1 - Agonistas receptores de oxitocina - Google Patents
Agonistas receptores de oxitocinaInfo
- Publication number
- AR078304A1 AR078304A1 ARP100103440A ARP100103440A AR078304A1 AR 078304 A1 AR078304 A1 AR 078304A1 AR P100103440 A ARP100103440 A AR P100103440A AR P100103440 A ARP100103440 A AR P100103440A AR 078304 A1 AR078304 A1 AR 078304A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- halogen
- amino acid
- side chain
- acid selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se relaciona con compuestos agonistas receptores de oxitocina, composiciones farmacéuticas que comprenden los mismos, uso de los mencionados compuestos para la elaboracion de un medicamento para el tratamiento de, inter alia, dolor abdominal, síndrome de colon irritable (SCI), autismo, disfuncion eréctil, disfuncion sexual femenina, induccion del parto y mantenimiento, induccion de la lactancia y mantenimiento, hemorragia postparto, Desorden de Estrés Post Traumático (DEPT), dolor, ansiedad y demás estados, como asimismo los métodos para el tratamiento de los mencionados estados, en donde se administran dichos compuestos. Reivindicacion 1: Un compuesto representado por la Formula estructural (1) en donde W y X se seleccionan independientemente de CH2 y S, pero ambos no pueden ser CH2; A es un aminoácido seleccionado de: alanina sustituida en la cadena lateral con un anillo heteroaromático de 5- o 6- miembros; tirosina; y fenilalanina sustituida en el anillo fenilo con halogeno, C1-4 alcoxi, C1-4 alquilhidroxi, C1-4 alquilo o amino; B es un aminoácido seleccionado de: isoleucina; y glicina sustituido en el alfa-carbono con C4-6 cicloalquilo; C es un aminoácido seleccionado de: prolina, opcionalmente sustituida en la cadena lateral con hidroxilo, C1-4 alcoxi, halogeno o azida, y prolina con su cadena lateral opcionalmente interrumpida por un heteroátomo y cuya cadena lateral opcionalmente interrumpida está opcionalmente sustituida con C1-4 alquilo; D es un aminoácido seleccionado de: leucina; homoleucina; isoleucina; y glicina sustituida en el alfa-carbono con C4-6 cicloalquilo; y E es un aminoácido seleccionado de: glicina y azaglicina, con la salvedad de que si C es 4-hidroxiprolina, entonces A deberá ser sustituida ya sea por fenilalanina en el anillo fenilo con halogeno, o C1-4 alquilhidroxi, y si C es 4-hidroxiprolina y A es fenilalanina sustituida en el anillo fenilo con halogeno, entonces ya sea B o D deberá ser glicina sustituida en el alfa-carbono con C4-6 cicloalquilo, o D deberá ser isoleucina, con la otra salvedad de que si A es fenilalanina sustituida en el anillo fenilo con C1-4 alquilo o halogeno, entonces C deberá ser prolina o prolina sustituida en la cadena lateral con halogeno, con la otra salvedad de que si A es fenilalanina sustituida en el anillo fenilo con halogeno, entonces ya sea B o D deberán ser glicina sustituida en el alfa-carbono con C4-6 cicloalquilo, o D deberá ser isoleucina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24432709P | 2009-09-21 | 2009-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078304A1 true AR078304A1 (es) | 2011-10-26 |
Family
ID=43629442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103440A AR078304A1 (es) | 2009-09-21 | 2010-09-21 | Agonistas receptores de oxitocina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8748564B2 (es) |
| EP (1) | EP2491052A2 (es) |
| JP (1) | JP5750443B2 (es) |
| KR (1) | KR20120093840A (es) |
| CN (1) | CN102656183B (es) |
| AR (1) | AR078304A1 (es) |
| AU (1) | AU2010295294B2 (es) |
| BR (1) | BR112012006185A2 (es) |
| CA (1) | CA2774593C (es) |
| IL (1) | IL218649A (es) |
| IN (1) | IN2012DN02103A (es) |
| MX (1) | MX2012003208A (es) |
| NZ (1) | NZ598579A (es) |
| RU (1) | RU2539692C2 (es) |
| SA (1) | SA110310710B1 (es) |
| TW (1) | TWI463990B (es) |
| WO (1) | WO2011035330A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| HUE039848T2 (hu) | 2012-12-21 | 2019-02-28 | Hoffmann La Roche | Peptidek oxitocin agonistákként |
| EA030091B1 (ru) * | 2014-06-03 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | Пептиды, выполняющие роль агонистов окситоцина |
| CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| WO2016025629A1 (en) | 2014-08-12 | 2016-02-18 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
| CA2957224A1 (en) | 2014-09-19 | 2016-03-24 | Ferring B.V. | Method of treating prader-willi syndrome |
| MX2017005692A (es) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
| WO2017060339A1 (en) * | 2015-10-06 | 2017-04-13 | Ferring B.V. | New methods for making barusiban and its intermediates |
| CN106967155B (zh) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
| WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
| AU2018340867B2 (en) * | 2017-09-28 | 2021-05-27 | Kinoxis Therapeutics Pty Ltd | Metabolite inspired selective oxytocin receptor agonists |
| WO2019180269A1 (en) | 2018-03-23 | 2019-09-26 | Cytoo | Alk5 inhibitors as skeletal muscle hypertrophy inducers |
| KR20210062648A (ko) | 2018-09-20 | 2021-05-31 | 레보 테라퓨틱스 인코포레이티드 | 카르베토신 완제의약품 및 이를 제조하는 방법 |
| EP3852723A4 (en) | 2018-09-20 | 2022-06-29 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
| AU2020380587A1 (en) | 2019-11-04 | 2022-01-06 | Ferring B.V. | Intranasal administration of merotocin for improving lactation |
| TW202304498A (zh) | 2021-03-26 | 2023-02-01 | 法商Ｏｔ４Ｂ公司 | 吞嚥困難之治療 |
| WO2023118303A1 (en) | 2021-12-21 | 2023-06-29 | Universitaet Wien | Highly stable oxytocin derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
| SE430885B (sv) * | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| CS216722B1 (en) * | 1980-06-24 | 1982-11-26 | Michal Lebl | Oxytocine analogues and method of making the same |
| US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| WO2002058721A1 (en) * | 2000-12-08 | 2002-08-01 | Baylor College Of Medicine | Trem-1 splice variant for use in modifying immune responses |
| ES2277640T3 (es) | 2002-02-27 | 2007-07-16 | Ferring Bv | Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina. |
| WO2007095021A2 (en) * | 2006-02-10 | 2007-08-23 | Ferring B.V | Novel compounds |
-
2010
- 2010-09-08 TW TW099130296A patent/TWI463990B/zh not_active IP Right Cessation
- 2010-09-20 SA SA110310710A patent/SA110310710B1/ar unknown
- 2010-09-21 KR KR1020127006787A patent/KR20120093840A/ko not_active Application Discontinuation
- 2010-09-21 MX MX2012003208A patent/MX2012003208A/es active IP Right Grant
- 2010-09-21 NZ NZ598579A patent/NZ598579A/en not_active IP Right Cessation
- 2010-09-21 JP JP2012529981A patent/JP5750443B2/ja not_active Expired - Fee Related
- 2010-09-21 WO PCT/US2010/049714 patent/WO2011035330A2/en active Application Filing
- 2010-09-21 AU AU2010295294A patent/AU2010295294B2/en not_active Ceased
- 2010-09-21 CA CA2774593A patent/CA2774593C/en not_active Expired - Fee Related
- 2010-09-21 RU RU2012110349/04A patent/RU2539692C2/ru not_active IP Right Cessation
- 2010-09-21 IN IN2103DEN2012 patent/IN2012DN02103A/en unknown
- 2010-09-21 EP EP10777131A patent/EP2491052A2/en not_active Withdrawn
- 2010-09-21 AR ARP100103440A patent/AR078304A1/es unknown
- 2010-09-21 US US13/496,269 patent/US8748564B2/en not_active Expired - Fee Related
- 2010-09-21 CN CN201080041788.0A patent/CN102656183B/zh not_active Expired - Fee Related
- 2010-09-21 BR BR112012006185A patent/BR112012006185A2/pt not_active IP Right Cessation
-
2012
- 2012-03-15 IL IL218649A patent/IL218649A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL218649A0 (en) | 2012-05-31 |
| CN102656183B (zh) | 2016-03-30 |
| WO2011035330A2 (en) | 2011-03-24 |
| CN102656183A (zh) | 2012-09-05 |
| AU2010295294A1 (en) | 2012-03-29 |
| US20120214733A1 (en) | 2012-08-23 |
| CA2774593C (en) | 2016-12-06 |
| NZ598579A (en) | 2014-02-28 |
| EP2491052A2 (en) | 2012-08-29 |
| AU2010295294A8 (en) | 2012-05-31 |
| JP5750443B2 (ja) | 2015-07-22 |
| TW201114434A (en) | 2011-05-01 |
| MX2012003208A (es) | 2012-05-29 |
| JP2013505269A (ja) | 2013-02-14 |
| RU2012110349A (ru) | 2013-10-27 |
| KR20120093840A (ko) | 2012-08-23 |
| BR112012006185A2 (pt) | 2016-05-31 |
| RU2539692C2 (ru) | 2015-01-27 |
| US8748564B2 (en) | 2014-06-10 |
| TWI463990B (zh) | 2014-12-11 |
| CA2774593A1 (en) | 2011-03-24 |
| IL218649A (en) | 2016-11-30 |
| WO2011035330A4 (en) | 2011-07-07 |
| AU2010295294B2 (en) | 2015-12-10 |
| SA110310710B1 (ar) | 2015-01-05 |
| IN2012DN02103A (es) | 2015-08-21 |
| WO2011035330A3 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078304A1 (es) | Agonistas receptores de oxitocina | |
| CL2012003132A1 (es) | Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo[e]azulenos, antagonistas del receptor de la vla; proceso de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual masculina o femenina, hipertension y cirrosis hepatica, entre otros. | |
| CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| EA201201309A1 (ru) | Фармацевтически активные производные двузамещенного триазина | |
| EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
| EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
| UA112804C2 (uk) | Амінотриазолопіридин для застосування в лікуванні запалення і його фармацевтичні композиції | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201190259A1 (ru) | Противовирусные соединения | |
| EA200970928A1 (ru) | Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения | |
| EA200971074A1 (ru) | Антивирусные соединения | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| EA201001722A1 (ru) | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции | |
| EA201200918A1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| CL2012002954A1 (es) | Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros. | |
| EA201291038A1 (ru) | Соединения пиразола в качестве ингибиторов jak | |
| CL2010001528A1 (es) | Compuestos derivados del acido 7-fenoxicroman-4-carboxilico sustituido; proceso de preparacion; compuesto intermediario; composicion farmaceutica de dicho compuesto; y su uso como antagonista de los receptores de prostaglandina d2 (pgd2) para tratar trastornos inmunologicos, enfermedades alergicas, trastornos inflamatorios. | |
| CO6210822A2 (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2 | |
| EA201401259A1 (ru) | Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| EA201390488A1 (ru) | Новые агонисты gpr 119 | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon | |
| PH12015502358A1 (en) | Highly concentrated formulations of soluble fc receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |